Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alterity Therapeutics ( (ATHE) ) has issued an update.
On 11 May 2026, Alterity Therapeutics reported new peer-reviewed data in NeuroImage showing that quantitative susceptibility mapping MRI can identify disease-specific iron accumulation in Multiple System Atrophy, distinguish MSA from Parkinson’s disease, and track disease severity using longitudinal and cross-sectional data from its bioMUSE Natural History Study. The findings validate QSM as an objective imaging biomarker that improves diagnostic accuracy, links iron burden to functional impairment, and supports the use of this imaging tool in Alterity’s ATH434 program, as the company advances toward an End-of-Phase 2 meeting with the U.S. Food and Drug Administration in mid-2026 to enable a Phase 3 trial in MSA.
The most recent analyst rating on (ATHE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and negative cash flows) and loss-driven valuation (negative P/E). Technicals provide partial support due to a strong uptrend, but overbought momentum signals temper the overall rating.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative conditions, with a primary focus on Multiple System Atrophy and related Parkinsonian disorders. Its lead oral candidate, ATH434, targets pathological brain iron accumulation and has shown clinically meaningful efficacy and favorable safety in Phase 2 trials, supporting plans for a pivotal Phase 3 program.
Average Trading Volume: 16,646
Technical Sentiment Signal: Buy
Current Market Cap: $86.55M
For an in-depth examination of ATHE stock, go to TipRanks’ Overview page.